Immunocellular receptors related to neurological disorders and therapeutic uses thereof
Class I major histocompatibility complex, is required in the activity-dependent refinement and plasticity of connections in the developing and adult central nervous system, demonstrating that molecules can perform critical roles in both systems. Similarities in the cellular signaling mechanisms of the immune and nervous systems provide for development of therapeutic and diagnostic agents in abnormal neuronal cellular function.
1. A method for identifying an agent that interacts with an immune related gene or gene product expressed in nervous tissue selected from the group consisting of Gp49, PIR, PIRA, PIRB, LIR, NKR-P1, NKp46, Digr1, ILT, MIR, KIR, class I MHC molecules, or fragments thereof, or expression products thereof, comprising contacting a candidate agent with the immune related gene, an allele of fragment thereof, or expression product thereof; quantitatively detecting an interaction between said immune related gene an allele of fragment thereof, or expression product thereof and the candidate agent, and separately contacting said candidate agent with neurons expressing said immune related gene in vitro or in vivo, and detecting an alteration in plasticity or activity-dependent remodeling in said neurons.
2. The method of claim 1 , wherein said immune related gene expressed in nervous tissue, or fragments thereof, or expression product thereof, or candidate agent comprises a label.
3. The method of claim 1 , wherein the immune related gene expressed in nervous tissue, or fragment or expression product thereof is provided on a solid support.
4. The method of claim 1 or 3 , wherein binding of the candidate agent with the immune related gene expressed in nervous tissue, or fragment or expression product thereof is detected.
5. The method of claim 1 , wherein the alteration is selected from the group consisting of an alteration in neuronal connectivity in neurons expressing said immune related genes, an alteration in an activity-dependent synaptic modification, an alteration in refinement of connections between the retina and a central target during development, and an alteration in long term potentiation or long term depression.
6. The method of claim 1 , wherein the candidate agent is a polypeptide, polynucleotide, or small molecule.